Is aTYR PHARMA INC (ATYR) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2025
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 16.5% / 30% | 89.3% / 30% | 2.2% / 30% | 1656.17% / 5% | ✗ NOT HALAL |
| DJIM | 16.5% / 33% | 89.3% / 33% | 2.2% / 33% | 1656.17% / 5% | ✗ NOT HALAL |
| MSCI | 13.7% / 33% | 74.5% / 33% | 1.8% / 33% | 1656.17% / 5% | ✗ NOT HALAL |
| S&P | 16.5% / 33% | 89.3% / 33% | 2.2% / 33% | 1656.17% / 5% | ✗ NOT HALAL |
| FTSE | 13.7% / 33% | 74.5% / 33% | 1.8% / 50% | 1656.17% / 5% | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 0.0% | |
| Operating Margin | -40856.3% | |
| Net Margin | 0.0% | |
| Return on Equity (ROE) | -108.1% | |
| Return on Assets (ROA) | -51.1% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$62M |
| Free Cash Flow | -$62M |
| Total Debt | $12M |
| Debt-to-Equity | 17.9 |
| Current Ratio | 5.3 |
| Total Assets | $93M |
Price & Trading
| Last Close | $0.79 |
| 50-Day MA | $0.87 |
| 200-Day MA | $2.30 |
| Avg Volume | 1.8M |
| Beta | 0.6 |
|
52-Week Range
$0.64
| |
About aTYR PHARMA INC (ATYR)
aTyr Pharma, Inc., a clinical stage biotechnology company, engages in the discovery and development of product candidates that translate tRNA synthetase biology into new therapies for fibrosis and inflammation in the United States. Its lead therapeutic candidate efzofitimod, a selective modulator of NRP2 that is in Phase 3 clinical trial for the treatment of pulmonary sarcoidosis; Phase 2 clinical trial to treat Sarcoidosis and systemic sclerosis- interstitial lung disease (ILDs); and treatment of other ILDs, such as chronic hypersensitivity pneumonitis (CHP) and connective tissue disease related ILD. The company is developing ATYR0101, a fusion protein derived from a domain of aspartyl-tRNA synthetase, which is in preclinical development for the treatment of fibrosis; and ATYR0750, a domain of alanyl-tRNA synthetase for the treatment of liver disorders. It has collaboration and license agreement with Kyorin Pharmaceutical Co., Ltd. for the development and commercialization of efzofitimod for ILDs in Japan. aTyr Pharma, Inc. was incorporated in 2005 and is headquartered in San Diego, California.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is aTYR PHARMA INC (ATYR) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), aTYR PHARMA INC is Not Halal. The company fails one or more screening criteria. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is aTYR PHARMA INC's debt ratio?
aTYR PHARMA INC's debt ratio is 16.5% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 13.7%.
What are aTYR PHARMA INC's key financial metrics?
aTYR PHARMA INC has a market capitalization of $74M, and revenue of $190,000. Return on equity stands at -108.1%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.